Presentation is loading. Please wait.

Presentation is loading. Please wait.

ERA-NET PathoGenoMics M. Karrasch, FZJ 13.01.2005 WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape PathoGenoMics ERA-NET.

Similar presentations


Presentation on theme: "ERA-NET PathoGenoMics M. Karrasch, FZJ 13.01.2005 WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape PathoGenoMics ERA-NET."— Presentation transcript:

1

2 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape PathoGenoMics ERA-NET WP 2 Policy maker workshop of common understanding: Survey on the national programmes 7th April 2005, Bonn

3 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape 9/049/069/099/089/059/07 WP 3 FR Strategic and analytic activities WP 4 FR Economic exploitation and job creation WP 5 FI Support for transnational consortium building WP 6 AT Human resources development and mobility WP 7 HU Management concept and tools WP 9 IL Science and society issues WP 8 SP Implementing transnational activities Contracts 1st round Contracts 2nd round Month WP 2 DE Knowledge base for RTD strategies WP 1 DE Status-quo of partner programmes WP 10 DE Consortium management

4 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Deliverable No.: D 1.2 Information documents on the national programmes Delivery date: due Month 5 (in January 2005) Nature:Report Dissemination level: PP Aim:Basis for development of best practices in programme implementation and management

5 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Questionnaire: Survey on the national RTD programmes  Part A:General Programme Description: A1: General Programme Information A2: History and Road Map of the Programme A3: Programme / Project statistics  Part B:Programme management and implementation approaches B1: Programme Initiation B2: Application / Submission Procedure B3: Evaluation Process B4: Financial modalities, Legal and Contractual Framework B5: Project management, administrative procedures and Review of programme and projects Questionnaire: Survey on the national RTD landscape  Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders

6 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape A: General Programme Description Part A:General Programme Description A1: General Programme Information A2: History and Road Map of the Programme A3: Programme / Project statistics Part B:Programme management and implementation approaches B1: Programme Initiation B2: Application / Submission Procedure B3: Evaluation Process B4: Financial modalities, Legal and Contractual Framework B5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders

7 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Preceding Programmes: no Programme Name: GEN-AU – Austrian Genome Research Programme Programme Owner: BMBWK – Federal Ministry of Education, Science and Culture Programme Management Agency: Programme Office GEN-AU Part of the larger Programme: no Topic: genome research Objective: e.g. enhance national competitiveness, strengthen research capacities, inprove conditions for investments Start Year: 2001 End year: 2010 Further information: Funding by: BMBWK 100% Total No. of funded projects: 2 No. of running projects: 2 Funded by the Programme: - 2 Universities - 1 public Research Institute Total funding volume per year: 10.0 mio € (2004) (0.47 mio € Pathog.) Fixed Bugdet: yes A: General Programme Description AT Next update / redesign: in process

8 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Programme Name: MICMAN – Microbes and Man Programme Owner: Academy of Finland and The Swedish Foundation for Strategic Research Programme Management Agency: National Public Health Institute Part of the larger Programme: no Topic: research on human-relevant microorganisms Objective: increase the knowledge of the interaction between host and microbe and apply this knowledge Start Year: 2003 End year: 2005 Further information: Funding by: Research Academy 76% Private foundation 24% Next update / redesign: none Total No. of funded projects: 15 No. of running projects: 15 ( 7 cons. of 2-4 Res. groups) Funded by the Programme: - 7 Universities - 2 public Research Institutes - 1 Regulatory Body Preceding Programmes: no Total funding volume per year: 1.8 mio € Fixed Bugdet: yes A: General Programme Description FI

9 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Programme Name: Programme Owner: Programme Management Agency: Part of the larger Programme Topic: Objective: Start Year: End year: Further information: Funding by: - Total No. of funded projects: List of running projects: Funded by the Programme: - Preceeding Programmes: - A: General Programme Description FR Next update / redesign: 8Fixed Budget: yes/no No data submitted

10 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Preceding Programmes: no Programme Name: Competence Center PathoGenoMik Programme Owner: BMBF – Federal Ministry of Education and Science Programme Management Agency: PTJ Part of the larger Programme: GenoMik (Genome Research in microorganisms) Topic: genome research on bacteria (GenoMik) Objective: use of the potential of microbial genomes for e.g. defeating human diseases Start Year: 2001 End year: 2006 Further information: Funding by: BMBF (88.9%) involved companies (11.1%) Total No. of funded projects: 47 No. of running projects: 44 Funded by the Programme: - 13 Universities - 2 Medical Centres - 4 public Research Institutes - 6 Companies Total funding volume per year: 3.63 mio € (BMBF) (2003) Fixed Bugdet: yes A: General Programme Description DE Next update / redesign: none

11 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Programme Name: Programme Owner: Programme Management Agency: Part of the larger Programme: Topic: Objective: Start Year: nd year: Further information: Funding by: Total No. of funded projects: No. of running projects: Funded by the Programme: Preceding Programmes: Total funding volume per year: Fixed Bugdet: A: General Programme Description HU Next update / redesign: No data submitted

12 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Programme Name: NA Programme Owner: CSO-MOH – The Chief Scientist Office, Ministry of Health Programme Management Agency: NA Part of the larger Programme: no Topic: Objective: Start Year: continous End year: continuos Further information: Funding by: CSO-MOH 100% Total No. of funded projects: 14 No. of running projects: 4 Funded by the Programme: - Universities - Medical Centres - public Research Institutes Preceding Programmes: no Total funding volume per year: 0.16 mio € (2003) Fixed Bugdet: no A: General Programme Description IL Next update / redesign: none

13 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Programme Name: Molecular and epidemiological study of multiresistence and genetic variability of infections Programme Owner: Latvian Council of Science Programme Management Agency: NA Part of the larger Programme NA Topic: Objective: Start Year: 1998 End year: 2005 Further information: Funding by: - LCS Total No. of funded projects: 9 No. of running projects:9 Funded by the Programme: - 100% Universities Preceeding Programmes: - funct. Stability of microb. cultures -Genotoxicity by microorganisms -Mol. Studies on Borrellia burgd. Total funding volume per year: 0,08 mio € A: General Programme Description LV Next update / redesign: 2005 Fixed Budget: yes

14 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Programme Name: Programme Owner: Programme Management Agency: Part of the larger Programme Topic: Objective: Start Year: End year: Further information: Funding by: - Total No. of funded projects: List of running projects: Funded by the Programme: - Preceeding Programmes: - Total funding volume per year:..mio € A: General Programme Description PT Next update / redesign: Fixed Budget: yes/no No data submitted

15 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Programme Name: (10 different programmes) Programme Owner: Ministry of Higher Education, Science and Technology Programme Management Agency: programme managers in diverse institutions/Universities Part of the larger Programme: national programme for financing research programmes Topic: 1. target research programme 2.mol. Biology of microorganisms; pharmacolog. Chemistry; nutrition and ecology of gastroint. Tract; toxins and biomembranes etc. Start Year: 2001 / 2004 End year: 2006 / 2008 Further information: website in slovenian language Funding by: -100% MESC -47% MESC -47% Min. of Agric. For. + Food -6% Min. of Health Total No. of funded projects: 800 List of running projects: 450 Funded by the Programme: - 11 Universities - 4 Medical Centers -39 Public Res. Inst. -1 priv. res. Inst. -1 company Preceeding Programmes: - No / yes Total funding volume per year: 0,496 mio € 2004 (6th them. Prior.) A: General Programme Description SV Next update / redesign: 2006 / 2008 Fixed Budget: no

16 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Programme Name: 1. Strategic Action on Genomics and Proteomics 2. Biotechnology Programme Owner: Ministry of Education and Science Programme Management Agency: NA Part of the larger Programme: National Plan of R&D Topic: different topics (e.g. genomics, proteomics etc.) Objective: functional analysis of genomes of human pathogens, characterisation of novel targets, pathogenicity mechanisms, host- pathogen-interactions, development of diagnostic tools Start Year: 2004 End year: 2007 Further information: web site in national language Funding by: MEC 100% Total No. of funded projects: 56 No. of running projects: 31 Funded by the Programme: - 19 Universities - 4 Medical Centres - 10 public Research Institutes Preceding Programmes: Yes National R&D plan Total funding volume per year: 1.42 mio € (2004) Fixed Bugdet: no A: General Programme Description ES Next update / redesign: 2007

17 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Next Programme update / redesign Partner Update / redesign date Austria In process Finland No re-design France Germany Programme ends 2006; no update, but new programme Hungary Israel Continous programme Latvia 2005 Portugal Slovenia 2006 Spain 2007

18 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape funded Institutions

19 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Project Analysis (projects related to PatoGenoMics) Austria Partner Total no. of projectsRange of annual budgets (1000 €) Average annual project budget (1000 €) Average duration of a project (months) Finland 15 (7 consortia of 2-4 groups) France Germany 47 (9 project groups of 1-7 groups) Hungary Israel Latvia 92 – Portugal Slovenia NA / 67 – 4036 / / 60 Spain 5612 – 165 / / 4436 / 36

20 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Part A:General Programme Description A1: General Programme Information A2: History and Road Map of the Programme A3: Programme / Project statistics Part B:Programme management and implementation approaches B1: Programme Initiation B2: Application / Submission Procedure B3: Evaluation Process B4: Financial modalities, Legal and Contractual Framework B5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders

21 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Programme Design Process Partner Top-down (idea was born and implemented by the funding authority) Bottom-up (idea was born by others e.g. beneficiaries of funding) Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain

22 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Programme / Call Contents / text First idea Ministries AT – BMBWK DE – BMBF Scientific communities: AT, FI, IL, LV, SL, ES Research councils AT, LV, SL Editing of the Call text Analysis Initiation phase: Who influences the programme design? Boards/ institutions: Scientific Advisory Board: AT, DE, LV Research Councils: AT, LV, SL Ministries/funding authorities/Committees AT – BMBWK FI – Steering Programme Committee DE – BMBF IL – CSO-MOH LV – Program leader SL – Ministry of Science and Technology ES– MEC influence

23 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape A: General Programme Description Part A:General Programme Description A1: General Programme Information A2: History and Road Map of the Programme A3: Programme / Project statistics Part B:Programme management and implementation approaches B1: Programme Initiation B2: Application / Submission Procedure B3: Evaluation Process B4: Financial modalities, Legal and Contractual Framework B5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders

24 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Electronical Application/Submission System Partner Electr. System used No electr. system Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain

25 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Rules for Submission System obligatory optional Austria Not availablePaper Version Finland Signature onlyElectr. System France Germany both Hungary Israel Latvia Portugal Slovenia Not availablePaper Version Spain Electr. System Partner Electr. SystemPaper VersionMost common subm. way

26 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Application Support Partner Written ManualElectronic guidance Helpdesk / contact person Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain

27 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Application Process: 1 step or 2 step approach Partner 1 step-approach (full proposals)2 step-approach (draft and full proposal Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain

28 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Steps during Application (draft proposal submission) (draft proposal evaluation): AT, FI Structure of draft: -Short description of the project -Organisational and scientific concept Summary: Application / Submission Procedure Support of applicants by: -Written manual: all except LV -Electr. Guidance: all -Helpdesk/contact person: all Approach: 2-step Drafts + full proposals: AT, FI Submission: -Electronically: FI, DE, IL, LV, ES -paper: AT, FI, DE, IL, LV, SL Elements of full proposals: -Name, coordinates, CV researcher(s) -scientific/technical description -Cost and time schedule -Management/organisation of networks -HR/ethical aspects -Relevance to programme -Relevance to industrial application Approach: 1-step full proposals: DE, IL, LV, SL, ES Rules of procedure by: - ministry: AT, DE, IL, SL, ES - Academy/Council: FI, LV full proposal submission full proposal evaluation: DE, IL, LV, SL, ES

29 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Is the call permanently open or are there cut-off dates? Partner Permanently open (no direct competition of proposals) Cut-off dates (direct competition of proposals) Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain

30 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape A: General Programme Description Part A:General Programme Description A1: General Programme Information A2: History and Road Map of the Programme A3: Programme / Project statistics Part B:Programme management and implementation approaches B1: Programme Initiation B2: Application / Submission Procedure B3: Evaluation Process B4: Financial modalities, Legal and Contractual Framework B5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders

31 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Partner Funding authority External advisory board Peer reviewHearing of applicant Presentation by applicant Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain Evaluation Process - Evaluation by:

32 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Evaluation Process: Stakeholders present among the evaluators Partner MinistryManage- ment Agency Research Council Industry Organi- sation Compa- ny Single Scientist Scientific Socie- ties Experts from abroad other Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain

33 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Evaluator characteristics Evaluators Evaluation by funding agency/authority: AT, FI, IL, LV, SL, ES Evaluation by external advisory board: AT, FI, DE, SL, ES Evaluation by peer review: AT, IL, SL From Industry: AT, (IL), LV, ES From abroad: AT, FI, DE, LV, ES Standing board: DE, LV, SL

34 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Are the Evaluators known to the Applicants? Partner yesno Austria Finland After the funding decision France Germany Some are known Hungary Israel Known post evaluation Latvia Portugal Slovenia Spain

35 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Can the final Evaluation result be overruled? Partner yesno Austria final decision is subject to the ministry Finland final ranking by the programme Steering committee France Germany Evaluation may be overruled by the project management agency and the ministry Hungary Israel Latvia Written complaint to Latvian Council of Science Portugal Slovenia Final decision by the funding bodies Spain

36 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Evaluation criteria Ethical issues Gender issues International competitiveness Internationality Innovative potential, novelty, scientific record of applicant / team Multidisciplinaritiy potential of applicant / team Project/resource management standard of written proposal Relevance to industrial Relevance to infrastructure Relevance to the programme Scientific quality of proposal Societal value Training aspects Transfer of expertise, mobility score Analysis: Evaluation Criteria

37 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Analysis: most important Evaluation Criteria

38 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Analysis: most important evaluation criteria Ranking Evaluation criteriaScore points 1 Innovative potential, novelty, originality21 2 Scientific quality of proposal19 3 Relevance to industrial application and commercialisation 15 4 Relevance to the programme14 5 potential of applicant / team13 5 scientific record of applicant / team13

39 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Partner Change of application/ evaluation procedure Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain Is it possible to change the rules of the application/evaluation procedure? possible impossible

40 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Austria Finland Germany Israel Latvia Slovenia Spain Partner months Time from funding notification of funding authority/agency till project start Time from full proposal evaluation till funding notification of funding authority/agency Time from full proposal submission till full proposal evaluation Time from draft proposal evaluation till full proposal submission Time from draft proposal submission till draft proposal evaluation Time from call publication to draft (full) proposal submission How long does it take from publication of a call till start of a project?

41 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape 40% from drafts 16% from drafts 23% 40% 16% 63% 0 10% 20% 30% 40% 50% 60% 70% AustriaFinlandGermanyIsraelLatviaSlovenia Spain project statistics: Average success rate of applications (drafts / full proposal versus funded projects)

42 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape A: General Programme Description Part A:General Programme Description A1: General Programme Information A2: History and Road Map of the Programme A3: Programme / Project statistics Part B:Programme management and implementation approaches B1: Programme Initiation B2: Application / Submission Procedure B3: Evaluation Process B4: Financial modalities, Legal and Contractual Framework B5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders

43 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Analysis: Funding possible impossible Partner Synchronous calls with national funding Joint calls with transnational funding Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain

44 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Analysis: cost models employed Country ATFIFRDEHUILLVPTSVES FC full cost with actual indirect costs FCF full cost with indirect flat rate costs AC additional costs with indirect flat rate costs other

45 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape A: General Programme Description Part A:General Programme Description A1: General Programme Information A2: History and Road Map of the Programme A3: Programme / Project statistics Part B:Programme management and implementation approaches B1: Programme Initiation B2: Application / Submission Procedure B3: Evaluation Process B4: Financial modalities, Legal and Contractual Framework B5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders

46 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Country ATFIFRDEHUILLVPTSVES Scientific/Technical Monitoring Written reports 1/year Oral reports/ interviews 1/year Site visit Seminar/conference 1/year 1/proj. Administrative/financial Monitoring Written reports 1/year1-4/ year 6/year2/year1/year Oral reports/ interviews Site visit occasi onally Seminar/conference Monitoring of ongoing projects

47 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape A: General Programme Description Part A:General Programme Description A1: General Programme Information A2: History and Road Map of the Programme A3: Programme / Project statistics Part B:Programme management and implementation approaches B1: Programme Initiation B2: Application / Submission Procedure B3: Evaluation Process B4: Financial modalities, Legal and Contractual Framework B5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders

48 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Relative economic Importance of Antiinfektives (2003) Partner Percentage of health expenses to GDP (%): percentage of pharmaceuticals to total health expenses (%): Total pharmaceutical retail market (maker’s price) (mio €): Anti-Infectives pharmaceutical retail market (mio €) Austria Finland France Germany 10,815, (7,4%) Hungary Israel 8,817,1 (1997) Latvia Portugal Slovenia 6,215,9362NA Spain (2002) 7,622, (6,33%)

49 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Rank GermanyIsraelSloveniaSpain 1 RATIOPHARM (114)TevaLek, d.d. (NA)GlaxoSmithKline 2 BAYER (104)RafaKrka, d.d., Novo Mesto (0,29) Aventis Pasteur MSD 3 PFIZER (96)AgisEsteve 4 AVENTIS (79)FarmaBayer 5 HEXAL (64)Lilly & Dista 6 GSK (51)Almirall Prodesfarma 7 ABBOTT (42)Farmacusi 8 FRESENIUS KAB.INTR (37) Vita Group 9 MSD (33)Bohm 10 ASTRAZENECA (32) Most important anti-infektives selling companies (antiinfektives sales per year in mio €)

50 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape A: General Programme Description Part A:General Programme Description A1: General Programme Information A2: History and Road Map of the Programme A3: Programme / Project statistics Part B:Programme management and implementation approaches B1: Programme Initiation B2: Application / Submission Procedure B3: Evaluation Process B4: Financial modalities, Legal and Contractual Framework B5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders

51 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Results of the national pathogenomics RTD landscape (expertise mapping etc.): (internal pages)

52 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape A: General Programme Description Part A:General Programme Description A1: General Programme Information A2: History and Road Map of the Programme A3: Programme / Project statistics Part B:Programme management and implementation approaches B1: Programme Initiation B2: Application / Submission Procedure B3: Evaluation Process B4: Financial modalities, Legal and Contractual Framework B5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders

53 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Analysis: Type of Research basic; 7 applied; 7 Demonstration; 1 other ; 0

54 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Analysis: Organisms studied – Phylogetenic Tree according to 16S-rRNA XIII Aquifex X Green Nonsulfur Bacteria IX Deinococcus / Thermus VIII Spirochaetes I Proteobacteria VII Green Sulfur Bacteria VI Bacteroides Flavobacteria group V Planctomyces, Pirella IV Chlamydia III Cyanobacteria II Gram positive Bacteria XI Thermotoga XII Thermo- desulfobacterium I Proteobacteria II Gram positive Bacteria IV Chlamydia VIII Spirochaetes

55 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Analysis: Organisms studied – Phylogetenic Tree according to 16S-rRNA I Proteobacteria IV Chlamydia VIII Spirochaetes XIII Aquifex X Green Nonsulfur Bacteria IX Deinococcus / Thermus VII Green Sulfur Bacteria VI Bacteroides Flavobacteria group V Planctomyces, Pirella III Cyanobacteria XI Thermotoga XII Thermo- desulfobacterium II Gram positive Bacteria

56 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Analysis: Organisms studied I Proteobacteria II Gram positive Bacteria Gram-positive cocci: e.g. Staphylococcus, Streptococcus, Pneumococcus Gram-positive non- sporulating rods: e.g. Listeria, Mycobacterium, Corynebacterium Gram-positive sporulating rods: e.g. Bacillus, Clostridium Gram-positive bacteria without cell wall: Mycoplasma Gram-negative rods: e.g. E. coli, Salmonella, Yersinia, Vibrio Haemophilus, Pasteurella, Helicobacter Obligatory intracellular bacteria: Chlamydia IV Chlamydia VIII Spirochaetes Gram-negative spiral bacteria: e.g. Borellia, Treponema

57 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Organism groups studied Gram – rods E. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter Gram + sporulating rods Bacillus, Clostridium Gram + without cell wall Mycoplasma Gram + cocci Staphylococcus, Streptococcus Gram + non-sporulating rods Listeria, Mycobacterium Eukaryotic organisms fungi Gram – spiral bacteria Borrellia obl. intracellular bacteria Chlamydia

58 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Organism groups studied Gram + sporulating rods Bacillus, Clostridium Gram + without cell wall Mycoplasma Gram + cocci Staphylococcus, Streptococcus Gram + non-sporulating rods Listeria, Mycobacterium Eukaryotic organisms fungi Gram – spiral bacteria Borrellia obl. intracellular bacteria Chlamydia Gram – rods E. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter

59 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Gram-negative rods: which are the most common studied species? E. Coli spec. E. Coli ETEC (toxin producing) E. Coli EHEC (enterohaemorragic) Yersinia enterolitica Yersinia spec. Salmonella typhi Salmonella spec. Shigella spec Pseudomonas spec.

60 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Gram-negative rods: which are the most committed countries?

61 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Organism groups studied Gram – rods E. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter Gram + sporulating rods Bacillus, Clostridium Gram + without cell wall Mycoplasma Gram + cocci Staphylococcus, Streptococcus Gram + non-sporulating rods Listeria, Mycobacterium Eukaryotic organisms fungi Gram – spiral bacteria Borrellia obl. intracellular bacteria Chlamydia

62 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Organism groups studied Staphylococcus spec. Staphylococcus aureus Staphylococcus epidermidis Streptococcus spec. Streptococcus pneumoniae Streptococcus pyogenes Pneumococcus spec. Enterococcus spec.

63 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Gram-positive cocci: which are the most committed countries?

64 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Organism groups studied Gram – rods E. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter Gram + sporulating rods Bacillus, Clostridium Gram + without cell wall Mycoplasma Gram + cocci Staphylococcus, Streptococcus Gram + non-sporulating rods Listeria, Mycobacterium Eukaryotic organisms fungi Gram – spiral bacteria Borrellia obl. intracellular bacteria Chlamydia

65 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Gram-positive non-sporulating rods : which are the most common studied species? Listeria monocytogenes Streptomyces spec. Mycobacterium spec. Mycobacterium tuberculosis Mycobacterium bovis

66 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Gram-positive non-sporulating rods : which are the most committed countries? Germany; 3 Israel; 1 Latvia; 2 Slovenia; 2 Spain; 5 Austria Finland Germany Israel Latvia Slovenia Spain

67 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Organism groups studied Gram – rods E. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter Gram + sporulating rods Bacillus, Clostridium Gram + without cell wall Mycoplasma Gram + cocci Staphylococcus, Streptococcus Gram + non-sporulating rods Listeria, Mycobacterium Eukaryotic organisms fungi Gram – spiral bacteria Borrellia obl. intracellular bacteria Chlamydia

68 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Eukaryotic Organisms: which are the most common studied ones? Yeast 3 Aspergillus 4 Candida 2 Plasmodium 2 Leishmania 3 Echinococcus 1 other; 4 Yeast Aspergillus Candida other (please specify): - other: Trypanosoma Plasmodium Leishmania Echinococcus granulosus other (please specify):

69 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Eukaryotic Organisms: which are the most committed countries? Finland; 1 Israel; 3 Slovenia; 4 Spain; 5 Austria Finland Germany Israel Latvia Slovenia Spain

70 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape

71 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape Analysis: Organisms studied – Phylogetenic Tree according to 16S-rRNA I Proteobacteria XIII Aquifex X Green Nonsulfur Bacteria IX Deinococcus / Thermus VIII Spirochaetes VII Green Sulfur Bacteria VI Bacteroides Flavobacteria group V Planctomyces, Pirella IV Chlamydia III Cyanobacteria II Gram positive Bacteria XI Thermotoga XII Thermo- desulfobacterium Alpha: e.g. Acetobacter, Agrobacterium, Gluconobacter, Paracoccus, Rhodospirillum, Rhizobium, Zymomonas Beta: e.g. Neisseria, Pseudomonas (some), Spirillum Gamma: e.g. Escherichia, Legionella, Salmonella and other intestine bacteria, Vibrio Delta: e.g. sulfate reducing bacteria, Myxobacteria, Xanthomonas (some) Epsilon: e.g. Campylobacter, Helicobacter, Xanthomonas (some)

72 ERA-NET PathoGenoMics M. Karrasch, FZJ WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape II Gram positive Bacteria Analysis: Organisms studied – Phylogetenic Tree according to 16S-rRNA XIII Aquifex X Green Nonsulfur Bacteria IX Deinococcus / Thermus VIII Spirochaetes I Proteobacteria VII Green Sulfur Bacteria VI Bacteroides Flavobacteria group V Planctomyces, Pirella IV Chlamydia III Cyanobacteria XI Thermotoga XII Thermo- desulfobacterium I Proteobacteria Non sporulating gram+ bacteria, low G+C content: e.g. Staphylococcus, Streptococcus, Micrococcus, Lactobacillus, Enterococcus, Listeria Endosporulating gram+ bacteria, low G+C content: e.g. Bacillus, Clostridium Bacteria without cell wall: Mycoplasma gram+ bacteria, high G+C content: e.g. Corynebacterium, Mycobacterium, Actinomycetes


Download ppt "ERA-NET PathoGenoMics M. Karrasch, FZJ 13.01.2005 WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape PathoGenoMics ERA-NET."

Similar presentations


Ads by Google